Genetic Testing Market Size and Forecast 2025–2033

The global Genetic Testing Market is poised for remarkable expansion over the next decade. The market is projected to grow from USD 21.47 billion in 2024 to approximately USD 49.72 billion by 2033, registering a robust CAGR of 9.79% between 2025 and 2033.

This growth trajectory reflects the rising integration of genomics into mainstream healthcare. Applications in oncology, rare disease diagnostics, prenatal screening, pharmacogenomics, and personalized medicine are significantly contributing to the market’s acceleration. As healthcare systems increasingly shift toward precision medicine, genetic testing is emerging as a cornerstone of early diagnosis, targeted therapy, and preventive healthcare strategies worldwide.

Download Free Sample Report:https://www.renub.com/request-sample-page.php?gturl=genetic-testing-market-key-players-analysis-p.php

Understanding Genetic Testing and Its Expanding Role

Genetic testing involves analyzing an individual's DNA, genes, chromosomes, or proteins to identify inherited disorders, genetic predispositions, and disease risks. It enables clinicians to detect mutations, assess susceptibility to specific illnesses, and tailor medical interventions accordingly.

In recent years, genetic testing has moved beyond hospital laboratories into consumer homes. The expansion of direct-to-consumer (DTC) testing services has empowered individuals to explore ancestry, health risks, and carrier status conveniently. Simultaneously, advancements in next-generation sequencing (NGS), molecular diagnostics, and bioinformatics have dramatically improved testing accuracy, affordability, and speed.

Key drivers reshaping the market include:

·        Growing awareness of preventive healthcare

·        Rising cancer prevalence requiring genomic profiling

·        Expanding newborn and prenatal screening programs

·        Increased investment in biotechnology research

·        Rapid progress in AI-powered data interpretation

Genetic testing now plays a pivotal role in oncology, where tumor genomic profiling guides targeted therapies. It is equally transformative in rare disease diagnostics, helping families receive earlier and more precise diagnoses.

Top 5 Companies in the Genetic Testing Market by 2033

1. Abbott Laboratories

Founded: 1888
Headquarters: United States

Abbott Laboratories is a global healthcare leader offering diagnostics, medical devices, nutritional products, and branded generic medicines. Its diagnostic portfolio includes core laboratory systems, rapid diagnostic tests, informatics solutions, and point-of-care systems.

With a vast global distribution network spanning North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa, Abbott maintains a strong foothold in clinical and molecular diagnostics, including genetic testing applications.

2. Illumina Inc.

Founded: 1998
Headquarters: San Diego, California

Illumina is a global pioneer in next-generation sequencing (NGS) technologies. The company provides integrated systems for analyzing genetic variation and biological functions. Its clientele includes pharmaceutical companies, genomic research centers, and biotechnology firms worldwide.

Illumina continues expanding geographically and technologically, enhancing accessibility to advanced sequencing tools across emerging markets.

3. F. Hoffmann-La Roche AG

Founded: 1896
Headquarters: Basel, Switzerland

Roche operates in pharmaceuticals and diagnostics, offering innovative treatments and advanced diagnostic tools. The company has developed numerous therapies and diagnostic platforms that support oncology, immunology, infectious diseases, and rare disorders.

Roche’s strong integration of diagnostics and therapeutics positions it uniquely in precision medicine.

4. Thermo Fisher Scientific Inc.

Founded: 2006
Headquarters: United States

Thermo Fisher Scientific supplies analytical instruments, specialty diagnostics, molecular biology systems, chromatography solutions, and life sciences tools. Its brands, including Thermo Scientific and Applied Biosystems, are widely recognized in clinical genomics and laboratory automation.

The company serves pharmaceutical companies, research institutions, universities, and government agencies worldwide.

5. Danaher Corporation

Founded: 1984
Headquarters: United States

Danaher develops diagnostic instruments, genomic consumables, filtration systems, and laboratory automation technologies. With manufacturing facilities across multiple continents, Danaher supplies products to biotechnology firms, healthcare facilities, and research institutions globally.

Product Launches Driving Innovation

Bio-Rad Laboratories, Inc.

In June 2024, Bio-Rad launched the ddSEQ™ Single-Cell 3' RNA-Seq Kit and Omnition v1.1 analysis software. Designed for single-cell transcriptome research, the solution enhances gene expression analysis across oncology, immunology, neurology, and stem cell biology.

Myriad Genetics, Inc.

In September 2025, Myriad Genetics partnered with SOPHiA GENETICS to develop a global liquid biopsy companion diagnostic test. The collaboration aims to support pharmaceutical companies in clinical trials through advanced molecular diagnostic capabilities and global test deployment.

SWOT Analysis Highlights

Diasorin S.p.A.

Diasorin’s core strength lies in its molecular diagnostics expertise and automated genetic testing platforms. Its LIAISON® MDX system enables high-throughput genetic analysis for clinical and research use. Continuous R&D investments and global distribution reinforce its leadership in next-generation diagnostic systems.

Quest Diagnostics Incorporated

Quest Diagnostics stands out due to its expansive laboratory infrastructure and clinical genomics leadership. With one of the world’s largest diagnostic networks, the company offers hereditary disease screening, oncology genomics, and pharmacogenomics services.

Its digital integration capabilities and partnerships with biopharmaceutical firms further enhance its precision medicine portfolio.

Recent Developments in the Genetic Testing Market

Revvity Inc.

In January 2025, Revvity partnered with Element Biosciences to commercialize an in vitro diagnostic workflow for neonatal sequencing. This initiative builds upon automated next-generation sequencing solutions and supports regulatory approval processes for advanced sequencing platforms.

QIAGEN N.V.

In April 2025, QIAGEN introduced new QIAseq panels for comprehensive genomic profiling and launched a QIAcuity digital PCR kit. The company also released an updated version of its somatic mutation database to support cancer genomic research.

Sustainability Goals in Genetic Testing

Laboratory Corporation of America Holdings

Labcorp aims to achieve net-zero greenhouse gas emissions by 2050. Its sustainability initiatives include renewable energy adoption, energy-efficient laboratory operations, waste reduction strategies, and responsible sourcing. The company also emphasizes health equity, employee well-being, and ethical governance.

Eurofins Scientific SE

Eurofins focuses on carbon neutrality, green laboratory practices, and renewable energy integration. Its sustainability strategy aligns with ESG principles, promoting eco-friendly logistics, waste minimization, and ethical sourcing across its global operations.

Market Segmentation and Analytical Coverage

The Genetic Testing Market report includes:

·        Historical Trends

·        Forecast Analysis (2025–2033)

·        Market Share Analysis

·        Company Profiles

·        SWOT Assessments

·        Revenue Analysis

·        Sustainability Evaluation

·        Product Benchmarking

Comprehensive company coverage includes:

Abbott Laboratories; Danaher Corporation; Illumina Inc.; Bio-Rad Laboratories, Inc.; F. Hoffmann-La Roche AG; Diasorin S.p.A.; Revvity Inc.; Thermo Fisher Scientific Inc.; QIAGEN N.V.; Myriad Genetics, Inc.; Quest Diagnostics Incorporated; Laboratory Corporation of America Holdings; Eurofins Scientific SE; Agilent Technologies, Inc.; BGI Genomics Co., Ltd.; Invitae Corporation; Natera, Inc.; PerkinElmer, Inc.; Biocartis N.V.; and Guardant Health, Inc.

Future Outlook: Precision Medicine at the Forefront

The future of genetic testing lies in deeper integration with artificial intelligence, big data analytics, and cloud-based bioinformatics platforms. As costs continue to decline and awareness rises, genetic testing will likely become a routine component of preventive healthcare.

Oncology will remain a dominant application area, but growth in prenatal testing, rare disease diagnostics, and pharmacogenomics will significantly broaden the market landscape. Regulatory frameworks, data privacy standards, and ethical considerations will shape the industry’s responsible expansion.

Final Thoughts

The Genetic Testing Market is on a transformative path, expanding from USD 21.47 billion in 2024 to USD 49.72 billion by 2033, growing at a CAGR of 9.79%. This growth reflects the accelerating shift toward personalized medicine, preventive healthcare, and genomics-driven treatment strategies.

As technological innovation converges with clinical application, genetic testing will redefine how diseases are diagnosed, treated, and prevented. Companies that invest in advanced sequencing technologies, sustainable laboratory practices, and global accessibility will lead the next era of precision healthcare—empowering individuals and healthcare providers with insights once unimaginable.